DO-BO

Do Swiss Reimbursement Reforms Open Doors—or Raise New Barriers, Petra Erni?

Tune in to this episode of MAP – The Market Access Podcast, to hear from Dr. Stefan Walzer as he speaks with Swiss reimbursement expert Petra Erni, who brings a rare perspective from both the industry and payer sides.

Together they explore the evolving Swiss drug reimbursement landscape, discussing the rise of cost consequence models, the growing role of health economic evidence, early access pathways, and strategic pricing challenges in Switzerland. Essential listening for pharma, market access, and health policy professionals—especially those eyeing the Swiss market.

Related

In the latest episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with pricing and access expert Shrutya Bhalla about how primary research must evolve in an era of AI, policy shocks, and accelerating market complexity. The key takeaway: high‑quality primary research is no longer just about collecting insights – it must […]

In this episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with Hatice Küçük Beton, Executive Director of the G20 Health and Development Partnership, about how to make global health truly investable – and keep it on the political agenda once the immediate crisis fades. They explore why high-level leadership, from Angela […]

In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voices in medtech regulation and former Head of the Medical Devices Division at Swissmedic – to unpack how regulation and market access truly fit together. They discuss why medical device regulation in Europe […]